Marshall Farms Group, LTD.

Marshall Farms Group, LTD., doing business as Marshall Bioresources, supplies laboratory animals—ferrets, Gottingen minipigs, and beagle dogs—to the federal government as a prime contractor on a full and open competitive basis, with no set-aside designations across its recent award footprint. The for-profit organization, headquartered in North Rose, New York, has been registered in SAM.gov since June 2000 and competes entirely as a prime, holding no subcontract positions in the available award data.

Marshall Bioresources' customer concentration is heavily weighted toward defense and military research. The Defense Health Agency dominates by both volume and dollars, accounting for 47 awards with $8.5 million combined potential value, followed by the Department of the Army Medical Command with 7 awards carrying $7.2 million. The DOD Uniformed Services University of the Health Sciences places 36 awards worth $2.4 million. Together, the top five funding agencies represent 85% of recent awards by count and 98% of combined potential value. The customer base extends to the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention Pittsburgh, and the Veterans Health Administration, reflecting a diversified federal research customer set anchored by defense and health research priorities.

Marshall Bioresources holds two significant indefinite delivery vehicles with the Defense Health Agency: a $3 million single-award Indefinite Delivery Contract for laboratory research ferrets running through October 26, 2028, and a $2.863 million single-award Blanket Purchase Agreement for Gottingen minipigs through December 14, 2029. Recent representative work includes a $32,507.83 delivery order issued January 23, 2026, for large animal research supporting clinical studies; a $30,991.25 delivery order from August 19, 2025, for male ferrets in support of approved research protocols; and a $33,660.15 delivery order from April 22, 2025, for veterinary services and laboratory animals. The company also supplies beagle dogs to the National Institutes of Health, as exemplified by a $12,986 purchase order awarded April 21, 2024. Performance occurs at Marshall Bioresources' facility in North Rose, New York, with animals shipped in filtered crates and including per diem coverage through shipment date where specified.

Activity has grown modestly year over year, from 2 awards in 2021 to 17 in both 2024 and 2025, with 4 awards visible through April 2026. Recent obligation rate stands at 14% of combined potential value across all awards, reflecting the nature of fixed-price delivery orders against standing IDVs issued as research demand arises. A recompete cliff of $124 thousand (combined potential value) exists in the next twenty-four months, limited to seven awards, indicating stable contract continuity under the two primary Defense Health Agency IDV vehicles. Marshall Bioresources' NAICS footprint is concentrated in All Other Animal Production (NAICS 112990), representing 110 of 124 awards, with minor exposure to Fur-Bearing Animal and Rabbit Production and Support Activities for Animal Production. The vendor's positioning as a specialized, sole-source supplier of live research animals places it at the intersection of defense medical readiness, biomedical research, and federal compliance with specialized animal husbandry and veterinary service delivery for critical research protocols supporting the U.S. Army Medical Research Institute of Chemical Defense, the U.S. Army Medical Research Institute of Infectious Diseases, and other military medical research entities.